可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1]Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes[J]. Nature, 2005, 436(7049):356-362.
[2]Xu M, Li XY, Wang JG, et al. Retinol-binding protein 4 is associated with impaired glucose regulation and microalbuminuria in a Chinese population[J]. Diabetologia, 2009, 52(8):1511-1519.
[3]Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity[J]. Hypertention, 2004, 43(5):993-1002.
[4]贾伟平,项坤三,陈蕾,等. 上海地区40岁以上自然人群中胰岛素抵抗现况及特征分析[J]. 上海医学, 2001, 24(4):199-201.
[5]Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system[J]. Drugs, 2004, 64(22):2537-2565.
[6]Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome[J]. Cardiovasc Diabetol, 2005,4:6.
[7]Yamada S, Ano N, Toda K, et al. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro[J]. Hypertens Res, 2008, 1(4):601-606.
[8]Ueshiba H, Miyachi Y. Effects of the long-acting calcium channel blockers,amlodipine,manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients[J]. Intern Med, 2004, 43(7):561-565.
[9]包玉倩,吴海娅,邱慧玲,等. 罗格列酮对2型糖尿病患者血清视黄醇结合蛋白4水平及肝脏脂肪含量的影响[J]. 上海医学, 2008, 31(11):767-770.
[10]Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events[J]. N Engl J Med, 2008, 359(12):1225-1237.